UK Markets close in 3 hrs 7 mins

MorphoSys AG (MOR.DE)

XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
26.77-0.54 (-1.98%)
As of 02:08PM CET. Market open.

MorphoSys AG

Semmelweisstrasse 7
Planegg 82152
Germany
49 89 89927 0
https://www.morphosys.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees771

Key executives

NameTitlePayExercisedYear born
Dr. Jean-Paul Kress M.D.Chairman of Management Board, MD & CEO2.06MN/A1965
Dr. Malte Peters M.D.Chief R&D Officer and Member of the Management Board1.18MN/A1962
Mr. Sung H. LeeCFO & Member of Management BoardN/AN/A1970
Mr. Klaus De WallHead of Accounting & TaxN/AN/AN/A
Ms. Lara Smith WeberHead of Controlling, Corp. Fin. & Corp. Devel.N/AN/AN/A
Dr. Margit UrbanHead of Discovery Alliances & TechnologiesN/AN/AN/A
Dr. Anja PomrehnSr. VP & Head of Investor RelationsN/AN/AN/A
Dr. Armin WeidmannHead of Compliance and Quality AssuranceN/AN/AN/A
Ms. Charlotte LohmannSr. VP & Gen. CounselN/AN/A1970
Mr. Thomas BiegiVP & Head of Corp. CommunicationsN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Corporate governance

MorphoSys AG’s ISS governance QualityScore as of 26 September 2021 is 1. The pillar scores are Audit: 5; Board: 1; Shareholder rights: 1; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.